# Eli Lilly

**Source:** https://geo.sig.ai/brands/eli-lilly  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Leader  
**Website:** lilly.com  
**Last Updated:** 2026-04-14

## Summary

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

## Company Overview

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Lilly's GLP-1 drug platform addresses the global obesity and type 2 diabetes epidemic through a dual mechanism tirzepatide formulation that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors — producing 15-22.5% average body weight reduction in clinical trials that surpasses the single-receptor GLP-1 agonists (like Ozempic/Wegovy from Novo Nordisk), which achieve 12-15% weight loss. This incremental efficacy advantage (the 22.5% maximum-dose result from the SURMOUNT-1 trial) creates the prescribing preference among endocrinologists and obesity medicine specialists that drives Mounjaro/Zepbound adoption despite Novo Nordisk's Ozempic first-mover advantage in the GLP-1 market. The concurrent approval of Zepbound for obstructive sleep apnea (2024, the first weight-loss drug approved for OSA) expands the treatable patient population beyond diabetes/obesity into a new therapeutic indication.

In 2025, Lilly competes in the GLP-1 weight loss, type 2 diabetes treatment, and Alzheimer's disease pharmaceutical market with Novo Nordisk (NASDAQ: NVO, Ozempic/Wegovy, ~$34B 2024 revenue), Roche (SIX: ROG, Alzheimer's and oncology), and AstraZeneca (NASDAQ: AZN, diabetes and oncology) for GLP-1 prescription volume, cardiometabolic disease management market share, and Alzheimer's therapeutic adoption. The $1 trillion market capitalization reflects investor conviction in Lilly's 10-year growth runway: obesity treatment addressable market estimates range from $50-100 billion annually by 2030 (with only 3-5% of eligible patients currently prescribed GLP-1 drugs), oral orforglipron (if approved) would remove the injection barrier for the majority of obesity patients who decline injectable treatment. The 2025 strategy focuses on expanding Mounjaro/Zepbound manufacturing capacity to reduce supply constraints, launching orforglipron in Phase 3 for obesity and diabetes, and commercializing Kisunla for Alzheimer's through neurologist prescribing education.

## Frequently Asked Questions

### What is Eli Lilly and Company?
Eli Lilly and Company is the world's most valuable pharmaceutical company, headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company discovers, develops, manufactures, and markets medicines for diabetes, obesity, Alzheimer's disease, cancer, and other conditions. Lilly operates in 18 countries with products sold in approximately 125 countries and achieved $45 billion in revenue in 2024. The company became the first healthcare company to reach $1 trillion market capitalization in November 2024.

### When was Eli Lilly founded?
Eli Lilly and Company was founded on May 10, 1876, by Colonel Eli Lilly in Indianapolis, Indiana. Lilly was a Civil War veteran and pharmaceutical chemist who opened a pharmaceutical laboratory on Pearl Street. In his first year of business, sales reached $4,470, growing to $48,000 by 1879. The company was formally incorporated in 1881 with a board of directors and stock issued to family members and close associates.

### Where is Eli Lilly headquartered?
Eli Lilly is headquartered in Indianapolis, Indiana, where it was founded in 1876. The company maintains its global headquarters in Indianapolis and has operations in 18 countries worldwide, with products sold in approximately 125 countries. Lilly is constructing a new $5 billion manufacturing facility in Goochland County, Virginia, for bioconjugates and monoclonal antibodies.

### What are Eli Lilly's most important products?
Lilly's most important products in 2024 are tirzepatide (Mounjaro for diabetes and Zepbound for obesity/sleep apnea), accounting for 37% of revenues; Trulicity (dulaglutide) for diabetes (12% of revenues); Humalog (insulin lispro) for diabetes (5% of revenues); and newly approved Kisunla (donanemab) for Alzheimer's disease. Historically, Lilly was first to mass-produce insulin (1923), the polio vaccine (1955), and recombinant DNA insulin Humulin (1982).

### What is Mounjaro and Zepbound?
Mounjaro and Zepbound are both brand names for tirzepatide, a dual GIP/GLP-1 receptor agonist. Mounjaro was approved in May 2022 for type 2 diabetes, while Zepbound was approved in November 2023 for obesity and later for obstructive sleep apnea. Together, they represent Lilly's flagship products and became blockbusters, generating $10.1 billion in Q3 2024 sales alone. Tirzepatide accounts for 37% of Lilly's total 2024 revenues and helped propel the company to $1 trillion market cap.

### How much does Eli Lilly's insulin cost?
In March 2023, Eli Lilly announced a $35 cap on the price of monthly insulin for eligible patients and reduced the list price of Humalog from $275 per month to $66 per month. This dramatic price reduction improved access to life-saving insulin for millions of Americans. Lilly also offers the Lilly Cares Patient Assistance Program, which provides free medications to eligible patients who meet income and insurance requirements.

### Who is the CEO of Eli Lilly?
David A. Ricks is the Chair and Chief Executive Officer of Eli Lilly and Company. He became CEO in January 2017 and was elected Chair in June 2017. Ricks joined Lilly in 1996 as a business development associate and held various leadership roles before becoming CEO. Under his leadership, Lilly has delivered record R&D output and business results, achieving $45 billion in revenue in 2024. In 2024, Ricks earned $114 million in compensation.

### What is Eli Lilly's financial performance?
Eli Lilly achieved approximately $45 billion in full-year 2024 revenue, representing 32% growth from 2023. Q4 2024 revenue was $13.53 billion, up 45% from Q4 2023. Net income in Q4 was $4.41 billion with EPS of $4.88. For 2025, Lilly projects revenue between $58.0-61.0 billion and EPS of $22.05-23.55. The company reached $1 trillion market capitalization in November 2024, making it the first healthcare company to achieve this milestone.

### What is the Lilly Cares program?
Lilly Cares is a patient assistance program that provides free Lilly medications to eligible U.S. residents (including Puerto Rico and U.S. Virgin Islands) who meet income and insurance requirements. Eligible patients must have a prescription from a healthcare provider, not be enrolled in Medicaid or full Low Income Subsidy or Veterans Benefits. Approved patients receive free medications shipped to their home or provider's office. Enrollment typically lasts 12 months. For questions, contact Lilly Cares at 1-800-545-6962.

### Is Eli Lilly hiring?
Yes, Eli Lilly employs over 43,000 people globally and regularly hires across research, development, manufacturing, commercial, and support functions. The company maintains a low 7% attrition rate (2024), below industry averages, indicating strong employee satisfaction. Lilly offers comprehensive benefits through its Global Well-Being Framework, professional development through the Explore Your Career platform, and has been recognized as one of Business Insider's Top 50 Best Companies to Work for in America.

### What awards has Eli Lilly won?
Eli Lilly has received numerous awards including Business Insider's Top 50 Best Companies to Work for in America, Forbes' The Just 100, Fortune Magazine's World's Most Admired Companies, and Ethisphere's World's Most Ethical Companies. In 2024, Lilly became the first pharmaceutical company to reach $1 trillion market capitalization. The company is also recognized for clinical research excellence, corporate responsibility, and employee benefits.

### What is Eli Lilly doing about Alzheimer's disease?
In 2024, Eli Lilly received FDA and UK approval for Kisunla (donanemab), a monoclonal antibody for treating Alzheimer's disease. Kisunla represents a major breakthrough in neurodegenerative disease therapy by targeting amyloid plaques in the brain. The approval followed successful clinical trials demonstrating the drug's ability to slow cognitive decline in patients with early Alzheimer's disease. Lilly's neuroscience division, led by President Anne White, continues to advance the company's pipeline in this critical therapeutic area.

## Tags

healthtech, b2b, saas, north-america, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*